SRA's number for the day: 7
This article was originally published in SRA
Executive Summary
As of 31 July, the Food and Drug Administration's Center for Biologics and Research had denied seven of the eight applications it had so far received from drug companies requesting that the agency review their investigational medicine under the breakthrough therapy designation pathway1.